Rocket to sell PRV for $180m to advance gene therapy pipeline
Rocket Pharmaceuticals has signed an agreement to sell its rare paediatric disease priority review voucher (PRV) for $180m to advance…
All articles by Salong Debbarma
Salong Debbarma
-
-
BioMarin acquires Amicus Therapeutics for $4.8bn
BioMarin Pharmaceutical has completed its acquisition of Amicus Therapeutics, buying the company for $14.50 per share in an all-cash deal…
-
FDA approves AstraZeneca’s Saphnelo for SLE
AstraZeneca has received approval from the US Food and Drug Administration (FDA) for the subcutaneous self-administration of Saphnelo (anifrolumab-fnia) using…
-
Novartis secures pair of regulatory wins for skin disease and malaria treatments
Novartis has netted a pair of regulatory wins, winning European approval for an oral therapy in chronic spontaneous urticaria (CSU)…
-
Sun Pharma to acquire Organon for $11.75bn
Sun Pharmaceutical Industries has signed a definitive agreement to acquire Organon in a transaction with an enterprise valuation of $11.75bn in cash,…
-
OZMOSI and Planview partner to enhance pharmaceutical data integration
OZMOSI and Planview have formed a partnership to support pharmaceutical organisations by integrating Ozmosi’s structured, machine-readable clinical datasets with Planview’s…
-
Cumberland to sell drug portfolio to Apotex for $100m
Cumberland Pharmaceuticals has agreed to sell its branded commercial drug portfolio to Canadian pharmaceutical company Apotex for $100m in cash.…
-
Sanofi receives FDA approval for Tzield in paediatric diabetes
Sanofi has received approval from the US Food and Drug Administration (FDA) for a supplemental biologic licence application for Tzield…
-
MSD teams up with Google Cloud on agentic AI transformation
Merck & Co (MSD) and Google Cloud have formed a multi-year partnership, investing up to $1bn, to advance agentic AI…
-
BioAegis and Prenosis partner for inflammatory disease therapies
BioAegis Therapeutics has entered a strategic partnership with Prenosis to advance AI-driven precision medicine for inflammatory diseases. The collaboration will…